Hadlima® PushTouch®
INN: adalimumab
Approved for use in:
Crohn’s Disease (moderate-severe)
Ulcerative Colitis (moderate-severe)
Type/Class
Biosimilar
Delivery Route
Subcutaneous Injection
Health Canada Approval
2019
Storage
Refrigerate between 2 and 8°C, do not freeze, keep in original carton to protect from light, may be stored at room temperature (up to 25°C) for a single period (length of which varies depending on dosage).
Use in Older Adults (65+)
May be used, please consult your doctor.
Pregnancy Indication
No pattern of major birth defects has been observed; infants may be at increased risk for infection.
Breastfeeding Indication
Low exposure levels due to large molecule size and degradation by GI tract.
Pediatric Indication
Not authorized for pediatric IBD patients.
Learn More
View the Hadlima® PushTouch® product monograph.
